ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
92,507.96
0.57%
S&P 500
6,021.63
0.57%
Dow Jones
44,860.31
0.28%
US Dollar vs Yen
152.706
-0.20%
Brent Oil
72.235
-0.30%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Ultragenyx Pharmaceutical Inc (RARE)

  7. Ultragenyx Pharmaceutical Inc (RARE) ニュース

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:RARE
日付受信時刻ニュースソース見出しコード企業名
2024/11/2706 : 30GlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in DecemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/11/2106 : 30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/11/1220 : 03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/11/1000 : 30GlobeNewswire Inc.Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science SummitNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/11/0606 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/11/0606 : 01GlobeNewswire Inc.Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/10/3005 : 05GlobeNewswire Inc.Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/10/1905 : 30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/10/1205 : 48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/10/0721 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/10/0721 : 00GlobeNewswire Inc.Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis ImperfectaNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/10/0405 : 34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/10/0405 : 30GlobeNewswire Inc.Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson DiseaseNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/09/2621 : 00GlobeNewswire Inc.Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual MeetingNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/09/1906 : 00GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/09/1902 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/09/0600 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/08/3005 : 30GlobeNewswire Inc.Ultragenyx to Participate in Investor Conferences in SeptemberNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/08/2320 : 00Business WireTactical Resources, a Growing North American Rare Earth Elements Company, to List on NASDAQNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/08/2205 : 30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/08/0205 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/08/0205 : 05GlobeNewswire Inc.Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/07/2605 : 05GlobeNewswire Inc.Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate UpdateNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/07/2421 : 00GlobeNewswire Inc.Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research SymposiumNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/07/2005 : 05GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/07/1805 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/07/1805 : 05GlobeNewswire Inc.Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome ProgramNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/07/1305 : 04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/06/2105 : 30GlobeNewswire Inc.Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:RAREUltragenyx Pharmaceutical Inc
2024/06/2103 : 23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RAREUltragenyx Pharmaceutical Inc
 Showing the most relevant articles for your search:NASDAQ:RARE

最近閲覧した銘柄

NASDAQ
AAPL
Apple
NYSE
JPM
JP Morgan Chase
COIN
DOGEUSD
Dogecoin
NYSE
NKE
Nike
NYSE
DIS
Walt Disney
NASDAQ
MSFT
Microsoft
COIN
ETHUSD
Ethereum
COIN
ADAUSD
Cardano
AMEX
SPY
SPDR S&P 500
USOTC
RHHBY
Roche (QX)
PM
XAUUSD
Gold vs US Dollar
SPI
SP500
S&P 500
USOTC
BNPQY
BNP Paribas (QX)
AMEX
XLF
Financial Select Sector
USI
USTECH100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有

BLACK FRIDAY

ADVFN

25周年を記念 1999-2024

Forexで最大60%オフ

1年間40％、2年間40％、*3年間60％

*3年間で¥ 153396、たったの¥ 61358